Mood disorders is a term that designates two main groups of disorders: depressive disorders, of which the most well-known is major depressive disorder (MDD), and bipolar disorder (BD), formerly known as manic-depression, where the patient experiences swings from depression to mania.
MDD is the most common psychiatric disorder, affecting approximately 21 million people in the US alone. The lifetime incidence of MDD in the United States is estimated at 20% in women and 12% in men, and approximately 254 million prescriptions for anti-depressants were written in 2010 in the US alone.
Despite the demonstrated potential for acute and long-term robust efficacy with treatment, approximately two-thirds of patients with MDD fail to adequately respond to treatment. Poor response to treatment is often the cause of misdiagnosis, making appropriate differential diagnosis critical to finding a treatment that will provide optimal efficacy.
At present, accurate diagnosis of mood disorders is difficult, and is based on an assessment of the severity of symptoms, making treatment outcome hard to measure. The need to find an objective measurement to help in the accurate diagnosis and management of the disorder and in predicting treatment outcome remains a significant unmet need in the management of depression.
elminda is currently evaluating, together with leading US psychiatric centers, the potential contribution of the BNA™ technology (assessment of similarity to reference healthy BNA patterns) for management of MDD and BD.
 IMS Health